Diverticulitis Disease

Diverticulitis Disease Market Outlook

The global diverticulitis disease market is projected to reach approximately USD 5.3 billion by 2035, growing at a CAGR of around 5.4% during the forecast period from 2025 to 2035. The increasing prevalence of diverticulitis, attributed to changing dietary habits and aging populations, is a primary growth factor for this market. Additionally, the rise in awareness regarding gastrointestinal diseases and advancements in diagnostic and treatment options have significantly contributed to market expansion. Moreover, the growing adoption of telemedicine and home healthcare services has further enhanced accessibility and convenience for patients, facilitating earlier diagnosis and more effective management of diverticulitis. The continuous development in healthcare infrastructure across various regions is also playing a pivotal role in boosting the market demand for diverticulitis-related healthcare services.

Growth Factor of the Market

The growth of the diverticulitis disease market is driven by several key factors, including an increase in the geriatric population, which is more susceptible to gastrointestinal disorders. A shift toward high-fat, low-fiber diets has heightened the incidence of diverticulitis, leading to an increased need for healthcare services and products related to the condition. Additionally, advancements in diagnostic technologies such as high-resolution imaging and minimally invasive surgical techniques have made it easier to detect and treat diverticulitis effectively. The rising trend of preventive healthcare and patient education initiatives has also contributed to heightened awareness about the symptoms and management of diverticulitis, leading to earlier interventions. Furthermore, the expansion of healthcare insurance coverage is making treatments more accessible, thereby driving market growth.

Key Highlights of the Market

• The global diverticulitis market is expected to reach USD 5.3 billion by 2035.
• North America currently holds the largest market share, accounting for approximately 45% of the total market.
• Antibiotics are anticipated to be the fastest-growing treatment option, driven by an increase in antibiotic resistance awareness.
• Complicated diverticulitis is seeing a notable rise due to delayed diagnosis and treatment.
• The market is characterized by rapid technological advancements in diagnostic methods and treatment options.

By Type

Uncomplicated Diverticulitis

Uncomplicated diverticulitis refers to the initial stage of the disease where patients experience inflammation of the diverticula without any significant complications. This form often presents mild symptoms such as abdominal pain, changes in bowel habits, and fever. The management typically involves outpatient treatment, including dietary modifications and antibiotics. The increase in the prevalence of this type is partly attributable to lifestyle changes and eating patterns, which can exacerbate the condition. As awareness grows, more patients are seeking diagnosis and treatment for uncomplicated diverticulitis, thereby driving market growth within this segment. Moreover, the ability to manage uncomplicated diverticulitis effectively with conservative treatment options contributes significantly to the segment's steady growth.

Complicated Diverticulitis

Complicated diverticulitis is a more severe manifestation of the disease, characterized by complications such as abscess formation, perforation, or fistula development. This form necessitates more aggressive treatment strategies, including potential hospital admission and surgical intervention. The rising incidence of this type is concerning, often linked to delays in diagnosis or ineffective management of uncomplicated cases. The complicated cases lead to increased healthcare costs due to prolonged hospital stays and surgical procedures, which significantly impacts the overall market. Moreover, the growing emphasis on surgical techniques and advancements in minimally invasive procedures are shaping the treatment landscape of complicated diverticulitis, enhancing patient outcomes and driving market growth.

By Diagnosis

Colonoscopy

Colonoscopy is considered the gold standard for diagnosing diverticulitis, allowing physicians to visualize the colon directly. This procedure not only aids in diagnosing the condition but also helps rule out other colonic diseases, making it an essential tool in clinical practices. The rising prevalence of colonoscopies as a routine diagnostic tool for gastrointestinal complaints has significantly boosted its utilization in diverticulitis diagnosis. Additionally, the increasing awareness of colorectal cancer screening is encouraging more patients to undergo this procedure, further driving demand. Innovations in colonoscopy techniques are enhancing accuracy and reducing discomfort, thus making it a preferred option for many healthcare providers.

CT Scan

CT scans are widely employed for diagnosing diverticulitis due to their ability to provide detailed images of the abdominal area. This imaging technique is particularly effective in identifying complications associated with diverticulitis, such as abscesses or perforation. The growing availability of advanced imaging technologies and the emphasis on rapid diagnosis in emergency settings have led to an increased reliance on CT scans. Moreover, their non-invasive nature and ability to yield quick results make CT scans an efficient choice for clinicians. The incorporation of artificial intelligence in imaging diagnostics is also expected to enhance the accuracy and speed of CT scans in identifying diverticulitis, thereby positively impacting market growth.

Blood Test

Blood tests are often utilized to assist in diagnosing diverticulitis by checking for signs of infection or inflammation, such as elevated white blood cell counts or C-reactive protein levels. While blood tests alone cannot confirm diverticulitis, they play a crucial role in conjunction with other diagnostic methods. The increasing focus on holistic diagnosis approaches in healthcare is driving the demand for blood tests as a preliminary assessment tool. Furthermore, advancements in blood testing technologies have made these tests quicker and more reliable, enhancing their role in the overall diagnostic process for diverticulitis. The integration of point-of-care blood tests is also aiding in the rapid evaluation of patients presenting with gastrointestinal symptoms, which is critical in emergency care settings.

Stool Test

Stool tests are valuable in the diagnostic process for diverticulitis, particularly in identifying gastrointestinal bleeding or infections. While not the primary diagnostic tool for diverticulitis, stool tests provide essential information that assists in comprehensive patient evaluation. The growing awareness of gastrointestinal health and the role of stool tests in screening for other conditions, such as infections or inflammatory bowel disease, has led to an increase in their usage. Additionally, the advancements in stool testing technology, such as the development of molecular diagnostics, are enhancing their accuracy and reliability. As healthcare systems increasingly emphasize preventive care and routine screenings, stool tests are likely to play a more significant role in the overall management of diverticulitis.

Sigmoidoscopy

Sigmoidoscopy is a diagnostic procedure used to examine the lower part of the colon and can be helpful in diagnosing diverticulitis. This method is usually less invasive than a full colonoscopy and can be performed in an outpatient setting. Sigmoidoscopy is particularly useful for assessing localized diverticular disease and can also assist in ruling out other possible causes of lower abdominal symptoms. The rising popularity of sigmoidoscopy as a screening tool, particularly in the context of colorectal cancer prevention, is boosting its application in diverticulitis diagnosis. The ability to perform biopsies during the procedure further enhances its diagnostic utility, thereby contributing to the segment's growth.

By Treatment

Antibiotics

Antibiotics play a crucial role in the management of diverticulitis, particularly in treating uncomplicated cases. They are utilized to combat the infection associated with diverticulitis and help reduce inflammation in the colon. The growing awareness of antibiotic resistance has prompted healthcare providers to explore alternative treatment regimens and adjust antibiotic strategies accordingly. Furthermore, developments in antibiotic formulations and the introduction of new classes of antibiotics are expected to enhance treatment effectiveness. In addition, the rising trend of personalized medicine is leading to tailored antibiotic prescriptions based on individual patient profiles, thereby improving outcomes in diverticulitis management. This evolving landscape is contributing to the steady growth of the antibiotics segment in the diverticulitis treatment market.

Pain Medication

Pain management is a significant component of diverticulitis treatment, as patients often experience abdominal discomfort and cramping. Over-the-counter pain relievers, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), are commonly used to alleviate pain symptoms. The increasing recognition of the importance of pain management in enhancing patient quality of life is driving demand for effective pain medication. Additionally, the rise in chronic pain awareness and the focus on multimodal pain management are encouraging healthcare professionals to adopt a more comprehensive approach to treating diverticulitis-related pain. As a result, the pain medication segment is expected to witness substantial growth, particularly with the development of targeted pain relief therapies.

Surgery

In cases of complicated diverticulitis, surgical intervention becomes necessary to address complications such as abscesses, perforations, or recurrent episodes of diverticulitis. Surgical options range from laparoscopic techniques to more invasive procedures, depending on the severity of the condition. The advancements in surgical technologies, including minimally invasive techniques, have significantly improved patient outcomes and reduced recovery times, making surgery a viable option for many patients. The increasing prevalence of complicated diverticulitis cases is driving the demand for surgical treatments, and the trend toward outpatient surgery is further expanding access. As surgical methods continue to evolve, the surgery segment within the diverticulitis market is poised for growth.

Dietary Changes

Dietary changes play a pivotal role in managing diverticulitis, particularly for individuals with recurrent episodes. Healthcare providers often recommend a high-fiber diet to improve bowel health and reduce symptoms. This lifestyle modification not only aids in symptom management but also helps prevent future complications. The growing awareness of the link between diet and gastrointestinal health is driving demand for dietary counseling and nutritional products tailored for diverticulitis patients. Furthermore, the increasing focus on preventive healthcare and wellness initiatives is encouraging individuals to adopt healthier eating habits, which bodes well for the dietary changes segment. As research continues to highlight the benefits of specific diets for diverticulitis management, this aspect of treatment is becoming increasingly important in the overall management strategy.

Lifestyle Changes

Lifestyle changes, including regular physical activity, hydration, and stress management, are essential components of diverticulitis management. Patients are often advised to incorporate exercise into their daily routines to promote bowel regularity and improve overall gastrointestinal health. The rising emphasis on holistic healthcare and wellness is driving awareness of the importance of lifestyle modifications in managing diverticulitis. Additionally, the growing trend of integrative health approaches is encouraging patients to seek guidance on how lifestyle choices influence their gastrointestinal health. Healthcare providers are increasingly focusing on educating patients about the role of lifestyle changes in preventing diverticulitis flare-ups, leading to the growth of this segment in the market.

By End User

Hospitals

Hospitals are pivotal in the management and treatment of diverticulitis, providing comprehensive care that includes diagnosis, treatment, and follow-up services. The increased admission rates for complicated cases, which often require surgical intervention, are driving the demand for hospital services. Additionally, hospitals are equipped with advanced diagnostic tools and specialists who can provide timely and effective treatment, making them a critical component of the healthcare system for diverticulitis patients. The growing prevalence of diverticulitis, coupled with advancements in hospital infrastructure and patient care pathways, is contributing to the robust growth of the hospital segment in the diverticulitis market.

Clinics

Clinics, particularly gastroenterology clinics, play an essential role in the early diagnosis and management of diverticulitis. With the rise of outpatient services and the emphasis on preventive healthcare, clinics are becoming increasingly popular among patients seeking timely diagnosis and treatment. The convenience and accessibility of clinics allow patients to receive personalized care without the need for hospitalization, which is particularly beneficial for those with uncomplicated diverticulitis. The growing trend of telehealth services is also enhancing the reach of clinics, allowing them to serve a broader patient population. As patient preferences shift towards outpatient care, the clinic segment in the diverticulitis market is expected to see significant growth.

Ambulatory Surgical Centers

Ambulatory surgical centers (ASCs) are gaining traction as an alternative to traditional hospital settings for surgical treatments of diverticulitis. These centers offer the advantage of same-day discharge, lower costs, and reduced wait times for patients requiring surgical intervention. The increasing focus on outpatient surgical options is driving the demand for ASCs, particularly for less severe cases of complicated diverticulitis. Furthermore, advancements in surgical techniques and anesthesia are enhancing the feasibility and safety of performing surgeries in an outpatient setting. As patients seek more cost-effective and convenient options for their healthcare needs, ambulatory surgical centers are poised for growth in the diverticulitis market.

Homecare

Homecare services are becoming increasingly important in the management of diverticulitis, particularly for patients recovering from surgery or those requiring ongoing care for chronic conditions. Homecare allows for personalized care plans tailored to individual patient needs, promoting comfort and faster recovery. The growing trend of telehealth and remote monitoring services is facilitating the delivery of care in a home setting, providing patients with access to healthcare professionals without the need for hospital visits. As the healthcare landscape shifts toward more patient-centered care models, the demand for homecare services in the diverticulitis market is expected to rise significantly. Additionally, the emphasis on reducing hospital readmissions is further driving the adoption of homecare solutions for diverticulitis patients.

By Region

North America is currently the largest market for diverticulitis, accounting for approximately 45% of the global market share. The prevalence of diverticulitis in this region is heightened due to lifestyle factors, including dietary habits and obesity rates. Additionally, advanced healthcare infrastructure and widespread access to diagnostic and treatment options are facilitating effective management of diverticulitis. The market in North America is anticipated to grow at a CAGR of 5.5% through 2035, driven by increasing healthcare expenditures and the rising geriatric population. Moreover, the growing trend of preventive healthcare and early diagnosis is expected to further enhance market growth in this region.

Europe holds the second-largest market share for diverticulitis, accounting for approximately 25% of the global market. The region is experiencing a rising incidence of diverticulitis, driven by similar lifestyle changes and dietary habits as observed in North America. The increasing availability of advanced diagnostic tools and treatment options is positively impacting the market. The European market is expected to witness a CAGR of 4.8% during the forecast period, fueled by growing awareness of gastrointestinal health and the emphasis on preventive care initiatives. Additionally, the growing trend of telemedicine and homecare services in Europe is anticipated to enhance accessibility for patients, contributing to overall market growth.

Opportunities

The diverticulitis market presents several opportunities for growth, particularly in the realm of advanced diagnostics and treatment options. With the rapid pace of technological advancements in medical imaging and minimally invasive surgical techniques, there exists a significant opportunity for companies that can innovate and offer state-of-the-art diagnostic tools or treatment modalities. For instance, the integration of artificial intelligence into imaging can enhance accuracy and efficiency in diagnosing diverticulitis, which can lead to better patient outcomes and reduced healthcare costs. Additionally, the development of personalized medicine approaches, including tailored dietary and lifestyle interventions, provides a unique opportunity for healthcare providers to address the specific needs of diverticulitis patients more effectively.

Moreover, as healthcare systems increasingly adopt telehealth solutions, there is an opportunity to enhance patient engagement and adherence to treatment plans. The ability to monitor patients remotely and provide timely interventions can significantly improve management strategies for diverticulitis, particularly for those who may have difficulties accessing traditional healthcare settings. Furthermore, as awareness of diverticulitis and its implications grows among the general population, there is a potential for increased demand for educational resources, support groups, and preventive care initiatives, thereby creating a comprehensive ecosystem for diverticulitis management. These factors collectively create fertile ground for innovation and investment in the diverticulitis market.

Threats

Despite the positive outlook for the diverticulitis market, several threats may hinder its growth. One primary concern is the increasing incidence of antibiotic resistance, which poses significant challenges for treating diverticulitis effectively. As patients become resistant to standard antibiotic therapies, healthcare providers may face difficulties in managing infections associated with the disease. This situation could lead to higher healthcare costs, extended hospital stays, and increased morbidity among patients. Additionally, the rising prevalence of chronic diseases such as obesity and diabetes, which are closely linked to gastrointestinal disorders, may complicate the management of diverticulitis and result in poorer patient outcomes.

Furthermore, the growing trend of self-medication and reliance on over-the-counter medications without professional guidance can exacerbate symptoms and lead to mismanagement of diverticulitis. With the proliferation of health information available online, patients may be inclined to seek unverified treatments or delay professional care, which could worsen their condition. The healthcare market's dynamic nature, influenced by regulatory changes and reimbursement challenges, also poses threats to the growth of the diverticulitis market. As providers navigate these complexities, maintaining a focus on patient-centered care and addressing emerging challenges will be crucial for successfully managing the diverticulitis landscape.

Competitor Outlook

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Pfizer Inc.
• Amgen Inc.
• Medtronic plc
• Boston Scientific Corporation
• Merck & Co., Inc.
• GSK plc
• Intuitive Surgical, Inc.
• Horizon Therapeutics plc
• Novartis AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Ferring Pharmaceuticals

The competitive landscape of the diverticulitis market is characterized by a diverse array of companies engaged in the development and provision of diagnostic tools, treatment options, and care services. Major pharmaceutical companies are focused on innovating antibiotic treatments and therapies to address the rising prevalence of diverticulitis and its complications. These companies are also investing in research and development to enhance the efficacy of existing treatment options and develop novel therapies that can provide better patient outcomes. The competitive dynamics are further influenced by partnerships and collaborations among healthcare providers, technology companies, and pharmaceutical firms, aiming to create integrated solutions for diverticulitis management.

Companies like AbbVie Inc. and Bristol-Myers Squibb are at the forefront of developing targeted therapies that address the underlying inflammation associated with diverticulitis. Their ongoing clinical trials and research initiatives aim to bring forth innovative treatment options that can significantly improve patient care. Additionally, Johnson & Johnson and Medtronic are focusing on advancing surgical techniques and minimally invasive procedures, which are crucial for managing complicated diverticulitis cases. Their investments in cutting-edge technology and surgical equipment are enhancing the overall treatment landscape, thereby contributing to their competitive advantage in the market.

Moreover, companies such as Boston Scientific and Abbott Laboratories are exploring the integration of diagnostic technologies, including imaging and biomarker assessments, to improve early detection and management strategies for diverticulitis. By enhancing diagnostic capabilities, these companies aim to empower healthcare providers to make more informed decisions regarding patient care. As the market continues to evolve, companies that prioritize innovation and adaptability will be well-positioned to capitalize on emerging opportunities in the diverticulitis landscape, ultimately improving patient outcomes and contributing to overall market growth.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GSK plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Medtronic plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Ferring Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Horizon Therapeutics plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Intuitive Surgical, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Boston Scientific Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Thermo Fisher Scientific Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Diverticulitis Disease Market, By Type
    • 6.1.1 Uncomplicated Diverticulitis
    • 6.1.2 Complicated Diverticulitis
  • 6.2 Diverticulitis Disease Market, By End User
    • 6.2.1 Hospitals
    • 6.2.2 Clinics
    • 6.2.3 Ambulatory Surgical Centers
    • 6.2.4 Homecare
  • 6.3 Diverticulitis Disease Market, By Diagnosis
    • 6.3.1 Colonoscopy
    • 6.3.2 CT Scan
    • 6.3.3 Blood Test
    • 6.3.4 Stool Test
    • 6.3.5 Sigmoidoscopy
  • 6.4 Diverticulitis Disease Market, By Treatment
    • 6.4.1 Antibiotics
    • 6.4.2 Pain Medication
    • 6.4.3 Surgery
    • 6.4.4 Dietary Changes
    • 6.4.5 Lifestyle Changes

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Diverticulitis Disease Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Diverticulitis Disease market is categorized based on

By Type

• Uncomplicated Diverticulitis
• Complicated Diverticulitis

By Diagnosis

• Colonoscopy
• CT Scan
• Blood Test
• Stool Test
• Sigmoidoscopy

By Treatment

• Antibiotics
• Pain Medication
• Surgery
• Dietary Changes
• Lifestyle Changes

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Pfizer Inc.
• Amgen Inc.
• Medtronic plc
• Boston Scientific Corporation
• Merck & Co., Inc.
• GSK plc
• Intuitive Surgical, Inc.
• Horizon Therapeutics plc
• Novartis AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Ferring Pharmaceuticals